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Medicines are having a terrific impact on the lives of
malaria patients. Great progress has been made with
understanding the safety and efficacy of fixed dose artemi-
sinin combination therapies, with five medicines either
prequalified by WHO or soon to be prequalified, allowing
treatment of children for as little as 25 cents. Artesunate
injections are now being established as standard of care for
severe malaria, offering significant improvement in health-
care, at a low cost from prequalified suppliers. Medicines
can also be used to protect vulnerable populations. Seaso-
nal malaria chemoprophylaxis can protect children for less
than 60 cents per year; chemoprophylaxis in pregnancy
has significant potential for the lives of the mothers and
babies. However, we are facing an infectious enemy, which
can and does develop resistance. New medicines are now
in phase II clinical trials which have the potential to over-
come any emerging resistance, and offer the hope for a
single dose cure. We have programs to develop new safer
molecules to block transmission of the parasite and to pre-
vent relapses, and these are starting to define potential
clinical candidates, after four years of investment. Finally,
the need for chemoprotection means that we need new
medicines with high potency and long duration. To facili-
tate these needs have released a ‘malaria box’: a set of 400
physical compounds, and also all the data on over 20’000
hits. Over the next few years, then innovative new partner-
ships with industry and academia based on this open
access to data will help us define a new era in antimalarial
drug development.
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